glp-1 ibs and semaglutide 🔎Real-world data on GLP-1RA switching & discontinuation in IBS pts Does GLP-1 Help with IBS?

Self-administering peptide combinations without bloodwork monitoring and clinical oversight is not responsible research practice

Archives June 2026 May 2026 April 2026 March 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 April 2024 March 2024 February 2024 December 2023 September 2023 July 2023 January 2023 November 2022 October 2022 September 2022 August 2022 May 2021 March 2021 February 2021 January 2021 October 2020 May 2020 November 2017 October 2017 August 2017 July 2017 June 2017 May 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 July 2016 June 2016 May 2016 March 2016 February 2016 December 2015 November 2015 October 2015 September 2015 August 2015 June 2015 May 2015 April 2014 March 2014 January 2014

Healthy Gut & Microbiome

The estimated fixed effects were a maximum percentage weight regain ( A ) of 75.3% (95% CI 68.981.6) and a recovery rate constant ( k ) of 0.0302 per week (95% CI 0.02020.0401), corresponding to a half-life of 23.0 weeks (95% CI 17.334.3)

For example, a worldwide shortage of semaglutide started to affect Australia in 2022 when Novo Nordisk could not supply enough Ozempic to meet an unexpected increase in demand due to off-label prescribing for weight loss

For example, HCPs should discuss the importance of balanced nutritional intake with all patients prescribed GLP-1 RAs, alongside monitoring signs of malnutrition, micronutrient status, and changes in body composition